• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild type H5N1 influenza challenge and co

tetano

Editor, Senior Moderator
J Virol. 2012 Sep 5. [Epub ahead of print]
Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild type H5N1 influenza challenge and control viral loads better than subunit H5N1 vaccine by eliciting high affinity antibodies.
Verma S, Dimtrova M, Munjal A, Fontana J, Crevar CJ, Carter DM, Ross TM, Khurana S, Golding H.
Source

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), 8800 Rockville Pike, Bethesda, MD, 20892.
Abstract

Recombinant hemagglutinin from influenza viruses with pandemic potential can be produced rapidly in various cell substrates. In the current study we compared the functionality and immunogenicity of bacterially produced oligomeric or monomeric HA1 proteins from H5N1 (A/Vietnam/1203/04) with the egg-based licensed subunit H5N1 (SU-H5N1) vaccine in ferrets challenged with homologous or heterologous H5N1 highly pathogenic influenza strains. Ferrets were vaccinated twice with the oligomeric or monomeric rHA1, or SU-H5N1 (Sanofi Pasteur) emulsified with Titermax adjuvant and were challenged with wild-type homologous (A/Vietnam/1203/04; clade 1) or heterologous (A/Whooperswan/Mongolia/244/2005; clade 2.2) virus. Only the oligomeric rHA1 (but not monomeric rHA1) immunogen and the SU-H5N1 vaccine provided protection from lethality and morbidity from homologous and heterologous HP-H5N1 challenge. Oligomeric rHA1 generated more cross-neutralizing antibodies and higher serum antibody binding to HA1 with stronger avidity & better IgG/IgM ratio compared to monomeric HA1 and SU-H5N1 vaccine using surface plasmon resonance (SPR). Importantly, viral loads after heterologous H5N1 challenge were more efficiently controlled in ferrets vaccinated with the oligomeric rHA1 immunogen than in SU-H5N1 vaccinated ferrets. The reduction of viral loads in the nasal washes correlated strongly with higher avidity antibodies to oligomeric rHA1 derived from H5N1 clade 1 and clade 2.2 viruses as measured by SPR. This is the first study to show the role of antibody avidity to the HA1 globular head domain in reduction of viral loads in upper respiratory tract, which could significantly reduce viral transmission.

PMID:
22951833
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22951833
 
Back
Top Bottom